New York University

Fernando Goni

Thomas M Wisniewski

Einar M Sigurdsson

Blas Frangione

Jose Alejandro Chabalgoity

The present invention is directed to polymerized products and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.

Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides

The present invention relates to antibodies and binding fragments thereof that bind the &#x3b2;-sheet secondary structure of a pathological monomeric or oligomeric non-fibrillar proteins without binding to the non-toxic, non-pathological forms of these proteins or peptides These antibodies and binding fragments thereof are suitable for the diagnosis, prevention, and treatment of protein conformational disorders including all amyloid diseases.

Specific murine and humanized monoclonal antibodies detecting pathology associated secondary structure changes in proteins and peptides

The present invention is directed to pharmaceutical agents and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.

Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins

The invention relates to methods for treating human amyloid disease by administration of modified A&#x3b2; peptide immunogens.

Method for treating amyloid disease

Vaccines against prion disease eliciting a humoral immune response when administered mucosally are described. The vaccines comprise a prion protein, a prion protein fragment, or a non-amyloidogenic prion protein homolog and an adjuvant suitable for inducing a humoral immune response after mucosal administration. Suitable adjuvants include cholera toxin subunit B, heat-labile enterotoxin and aluminum hydroxide. Alternatively, the vaccine comprises a vector encoding a prion protein, fragment, or homolog in an attenuatedhost. The vaccines can be used to prevent or treat prion disease in humans and other mammals.

Growing community of inventors

New York, NY, United States of America

Fernando Goni